Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis

Danielle Nicolazzo,1 Franz Kerdel,1 Francisco Kerdel1,2 1Florida Academic Dermatology Centers, The University of Miami Hospital, Miami, FL, USA; 2Florida International University, Miami, FL, USA Abstract: Psoriasis is a chronic inflammatory disease estimated to affect 1%–3% of the worldw...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nicolazzo D, Kerdel F
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/996958c3b99d48eca82e859392d8777d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:996958c3b99d48eca82e859392d8777d
record_format	dspace
spelling	oai:doaj.org-article:996958c3b99d48eca82e859392d8777d2021-12-02T00:25:36ZCritical appraisal of adalimumab in the treatment of chronic plaque psoriasis2230-326Xhttps://doaj.org/article/996958c3b99d48eca82e859392d8777d2014-06-01T00:00:00Zhttp://www.dovepress.com/critical-appraisal-of-adalimumab-in-the-treatment-of-chronic-plaque-ps-a17342https://doaj.org/toc/2230-326X Danielle Nicolazzo,1 Franz Kerdel,1 Francisco Kerdel1,2 1Florida Academic Dermatology Centers, The University of Miami Hospital, Miami, FL, USA; 2Florida International University, Miami, FL, USA Abstract: Psoriasis is a chronic inflammatory disease estimated to affect 1%–3% of the worldwide population. It is not simply a cutaneous disease but also poses a significant medical, social, and economic burden worldwide. Tumor necrosis factor (TNF)-α inhibitors are currently amongst the most important drugs in the therapeutic management of psoriasis. Patients using TNF-α inhibitors are at risk for infections including active and latent tuberculosis. Adalimumab, one of the TNF-α inhibitors, is a fully human monoclonal antibody that received approval for the treatment of chronic plaque psoriasis in 2008. Its use has been studied extensively for its safety and efficacy profile in the clinical setting. For the purpose of this review, we accessed the major publications in English relating to the use of adalimumab for psoriasis. Adalimumab appears to be one of the most efficacious biologic agents for the treatment of psoriasis. Results from various clinical trials including the REVEAL, CHAMPION, and BELIEVE are included in this review. The most recent data from an ongoing post-marketing study (ESPRIT) is also included in the analysis. Research regarding the safety, efficacy, and patient-reported outcomes support a favorable risk-benefit profile for adalimumab. Keywords: TNF-α inhibitor, safety, efficacy, outcomesNicolazzo DKerdel FKerdel FDove Medical PressarticleDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol 2014, Iss default, Pp 11-18 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dermatology RL1-803
spellingShingle	Dermatology RL1-803 Nicolazzo D Kerdel F Kerdel F Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
description	Danielle Nicolazzo,1 Franz Kerdel,1 Francisco Kerdel1,2 1Florida Academic Dermatology Centers, The University of Miami Hospital, Miami, FL, USA; 2Florida International University, Miami, FL, USA Abstract: Psoriasis is a chronic inflammatory disease estimated to affect 1%–3% of the worldwide population. It is not simply a cutaneous disease but also poses a significant medical, social, and economic burden worldwide. Tumor necrosis factor (TNF)-α inhibitors are currently amongst the most important drugs in the therapeutic management of psoriasis. Patients using TNF-α inhibitors are at risk for infections including active and latent tuberculosis. Adalimumab, one of the TNF-α inhibitors, is a fully human monoclonal antibody that received approval for the treatment of chronic plaque psoriasis in 2008. Its use has been studied extensively for its safety and efficacy profile in the clinical setting. For the purpose of this review, we accessed the major publications in English relating to the use of adalimumab for psoriasis. Adalimumab appears to be one of the most efficacious biologic agents for the treatment of psoriasis. Results from various clinical trials including the REVEAL, CHAMPION, and BELIEVE are included in this review. The most recent data from an ongoing post-marketing study (ESPRIT) is also included in the analysis. Research regarding the safety, efficacy, and patient-reported outcomes support a favorable risk-benefit profile for adalimumab. Keywords: TNF-α inhibitor, safety, efficacy, outcomes
format	article
author	Nicolazzo D Kerdel F Kerdel F
author_facet	Nicolazzo D Kerdel F Kerdel F
author_sort	Nicolazzo D
title	Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
title_short	Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
title_full	Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
title_fullStr	Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
title_full_unstemmed	Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
title_sort	critical appraisal of adalimumab in the treatment of chronic plaque psoriasis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/996958c3b99d48eca82e859392d8777d
work_keys_str_mv	AT nicolazzod criticalappraisalofadalimumabinthetreatmentofchronicplaquepsoriasis AT kerdelf criticalappraisalofadalimumabinthetreatmentofchronicplaquepsoriasis AT kerdelf criticalappraisalofadalimumabinthetreatmentofchronicplaquepsoriasis
_version_	1718403753431793664

Critical appraisal of adalimumab in the treatment of chronic plaque psoriasis

Ejemplares similares